Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,379 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neoplasms, Pancreatic Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer

NCT01492907
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
MeIQx, Pancreatectomy
Radiation · Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 1, 2026, 4:17 PM EDT
Completed Phase 2 Interventional

Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma

NCT01233375
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
CO-1.01
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
13
States / cities
Tucson, Arizona • Denver, Colorado • Boynton Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Oct 1, 2026, 4:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

NCT06598007
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
CT3001, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Drug
Lead sponsor
Crossignal Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 1, 2026, 4:17 PM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

NCT00066677
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
rhuMAB-VEGF, docetaxel
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 1, 2026, 4:17 PM EDT
Completed Phase 1 Interventional

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

NCT00967577
View directory record Official record
Conditions
Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Esophageal Cancer, Gliomas
Interventions
177Lu-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 1, 2026, 4:17 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer

NCT00336700
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Erlotinib
Drug
Lead sponsor
Herbert J. Zeh, III MD, FACS
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 1, 2026, 4:17 PM EDT
Completed Phase 1 Interventional

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

NCT00465725
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastrointestinal Neoplasm, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
Picoplatin
Drug
Lead sponsor
Poniard Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Atlanta, Georgia • Las Vegas, Nevada • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Oct 1, 2026, 4:17 PM EDT
Withdrawn Phase 1 Interventional

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

NCT05634525
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
MRTX849
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 1, 2026, 4:17 PM EDT
Completed Not applicable Interventional

Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Cancer Undergoing Surgery

NCT01646697
View directory record Official record
Conditions
Pancreatic Cancer, Adenocarcinoma
Interventions
cytology specimen collection procedure
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 1, 2026, 4:17 PM EDT
Completed No phase listed Observational

DNA Microarray Study of Pancreas Cancer

NCT00680420
View directory record Official record
Conditions
Pancreas Cancer
Interventions
fine needle aspiration biopsy
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 1, 2026, 4:17 PM EDT
Terminated Phase 1 Interventional

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

NCT02757391
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide, Laboratory Biomarker Analysis, Pembrolizumab
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 1, 2026, 4:17 PM EDT
Completed No phase listed Observational

Collecting Solid Tumor Tissue to Identify New Treatments

NCT01658917
View directory record Official record
Conditions
Gastrointestinal Cancer, Liver Cancer, Pancreatic Cancer, Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Oct 1, 2026, 4:17 PM EDT
Terminated Phase 1 Interventional

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

NCT05252390
View directory record Official record
Conditions
Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
Interventions
NUV-868, Olaparib, Enzalutamide
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 1, 2026, 4:17 PM EDT
Recruiting Phase 3 Interventional

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

NCT06593431
View directory record Official record
Conditions
Pancreas Cancer, Oligometastatic
Interventions
Consolidative Radiation
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Camden, New Jersey • Voorhees Township, New Jersey • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 1, 2026, 4:17 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT

NCT06412510
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Pancreatic Adenocarcinoma
Interventions
Prehabilitation
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 1, 2026, 4:17 PM EDT
Recruiting Not applicable Interventional

A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer

NCT07324096
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography with Contrast, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 1, 2026, 4:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

NCT05431270
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 1, 2026, 4:17 PM EDT
Not listed No phase listed Observational

Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study

NCT03951324
View directory record Official record
Conditions
Biliary Stricture, Pancreas Cancer, Cholangiocarcinoma, Bile Duct Cancer, Bile Duct Neoplasms Malignant, Bile Duct Neoplasms, Bile Duct Lesions, Bile Duct Obstruction, Bile Duct Diseases, Bile Duct Obstruction, Extrahepatic, Bile Duct Stenosi, Bile Duct Adenoma, Pancreatic Duct Stricture, Pancreatic Duct Stenosis, Pancreatic Duct Obstruction, Pancreatic Ductal Adenocarcinoma, Primary Sclerosing Cholangitis
Interventions
Interobserver agreement or Interrater agreement
Other
Lead sponsor
Innovative Digestive Health Education and Research Inc
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 1, 2026, 4:17 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

The STRONG Nutrition Support Study for People With Pancreatic Cancer

NCT07826780
View directory record Official record
Conditions
Pancreas Cancer, Metastatic, Pancreas Carcinoma
Interventions
STRONG intervention App, individualized remote dietitian
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 1, 2026, 4:17 PM EDT
Withdrawn Phase 2 Interventional

Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

NCT05216120
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Pemigatinib 4.5 MG
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 1, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Results available

Bupropion in Helping Adults Stop Smoking

NCT00534001
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
bupropion hydrochloride, placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 1, 2026, 4:17 PM EDT
Completed Phase 1 Interventional

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

NCT05440942
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Trametinib, Ruxolitinib, Retifanlimab
Drug
Lead sponsor
Peter Hosein, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 1, 2026, 4:17 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT06147037
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
Interventions
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 1, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer

NCT00366457
View directory record Official record
Conditions
Pancreatic Cancer, Adenocarcinoma of the Pancreas
Interventions
Bevacizumab, Erlotinib, Gemcitabine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 1, 2026, 4:17 PM EDT